Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, showed a ...

Fatty liver disease, caused by the accumulation of fat in the liver, is estimated to affect one in four people worldwide. If ...

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Altimmune shares rose 13% in premarket trading following an announcement it would present topline 24-week data from its Phase 2b trial evaluating pemvidutide as a treatment for those with metabolic ...

Altimmune Inc (NASDAQ: ALT) shares plunged after topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). The trial assessed three ...

Altimmune is a pioneer in creating peptide-based therapies for obesity and liver disease, with a unique approach to product development. Altimmune's R&D expenses have dropped year-on-year due to ...

The latest international Altimmune Inc news and views from Reuters - one of the world's largest news agencies. ... Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle.

Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome ...